Clinical Trials Logo

Clinical Trial Summary

This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS) patients.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00370032
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 4
Start date December 2006
Completion date December 2007

See also
  Status Clinical Trial Phase
Completed NCT01855711 - Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) Phase 2
Terminated NCT00423345 - Colon Investigation - Factors Determining Choice of Procedure
Completed NCT00101985 - Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS) Phase 2
Completed NCT00376896 - Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers Phase 1
Completed NCT00067561 - Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Phase 3
Completed NCT00067457 - Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Phase 3
Terminated NCT00461682 - Sb-705498 Rectal Pain Study Phase 2
Completed NCT00385099 - Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome Phase 2